Pfizer acquires rights to several generics from Aurobindo

03 March 2009

Pfizer Inc has entered into a series of agreements with Aurobindo Pharma Ltd to commercialise generic medicines, including pills and injectables, that are no longer patent protected, and have lost market exclusivity in the US and Europe, to push its established products business.

Pfizer's established products business unit, focuses on the commercialisation of products where market exclusivity has been lost. Currently, Pfizer's established products business unit has annual sales of $10 billion globally.

''Pfizer has acquired rights to 39 generic solid oral dose products in the US and 20 in Europe, and an additional 11 in France. The medicines cover a broad range of therapeutic areas, including cardiovascular disease and central nervous system disorders,'' Pfizer said in a release.

Pfizer expects the products acquired to deliver more than $200 million in annual revenue in 2013, according to David Simmons, general manager of Pfizer's established products business unit.

Pfizer said it planned to commercialised these products in the US through its Greenstone subsidiary. The company, however, did not disclose financial terms of the deal.

Pfizer has also acquired rights to 12 sterile injectable products in the US and Europe. These medicines are antibiotics, including penicillins and cephalosporins.